Credit Suisse Group Increases Alder Biopharmaceuticals (ALDR) Price Target to $19.00  Donna Armstrong | Aug 17th, 2018
Alder Biopharmaceuticals (NASDAQ:ALDR) had its price target boosted by Credit Suisse Group from $16.00 to $19.00 in a research note published on Monday. The brokerage currently has an outperform rating on the biopharmaceutical company's stock.
ALDR has been the subject of several other reports. BidaskClub cut Alder Biopharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, June 12th. Needham & Company LLC initiated coverage on Alder Biopharmaceuticals in a research report on Wednesday, June 27th. They set a buy rating and a $28.00 price objective for the company. Goldman Sachs Group initiated coverage on Alder Biopharmaceuticals in a research report on Tuesday, April 24th. They set a neutral rating and a $17.00 price objective for the company. Mizuho reaffirmed a buy rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research report on Thursday, June 7th. Finally, Zacks Investment Research cut Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, May 1st. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. The stock has a consensus rating of Buy and an average price target of $23.60. Get Alder Biopharmaceuticals alerts:
ALDR stock opened at $18.25 on Monday. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.73. The stock has a market cap of $1.31 billion, a PE ratio of -3.69 and a beta of 2.66. Alder Biopharmaceuticals has a fifty-two week low of $8.60 and a fifty-two week high of $20.87.
Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.01. equities research analysts anticipate that Alder Biopharmaceuticals will post -4.91 EPS for the current fiscal year.
In related news, Director Jeffrey T. L. Smith sold 12,161 shares of the stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $17.85, for a total transaction of $217,073.85. Following the completion of the transaction, the director now directly owns 7,952 shares of the company's stock, valued at $141,943.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . Also, insider John A. Latham sold 24,999 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $15.48, for a total value of $386,984.52. Following the transaction, the insider now directly owns 268,692 shares of the company's stock, valued at $4,159,352.16. The disclosure for this sale can be found here . Insiders have sold 102,087 shares of company stock valued at $1,785,094 over the last three months. Insiders own 17.40% of the company's stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ALDR. Geode Capital Management LLC boosted its position in Alder Biopharmaceuticals by 8.5% during the fourth quarter. Geode Capital Management LLC now owns 559,850 shares of the biopharmaceutical company's stock valued at $6,410,000 after purchasing an additional 43,864 shares during the last quarter. Deutsche Bank AG boosted its position in Alder Biopharmaceuticals by 25.3% during the fourth quarter. Deutsche Bank AG now owns 304,972 shares of the biopharmaceutical company's stock valued at $3,491,000 after purchasing an additional 61,611 shares during the last quarter. Teachers Advisors LLC boosted its position in Alder Biopharmaceuticals by 27.7% during the fourth quarter. Teachers Advisors LLC now owns 120,931 shares of the biopharmaceutical company's stock valued at $1,385,000 after purchasing an additional 26,233 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in Alder Biopharmaceuticals by 138.3% during the fourth quarter. TIAA CREF Investment Management LLC now owns 394,589 shares of the biopharmaceutical company's stock valued at $4,518,000 after purchasing an additional 229,010 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Alder Biopharmaceuticals during the fourth quarter valued at approximately $2,341,000.
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. Alder Biopharmaceuticals Alder Biopharmaceutical